Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Pioneering Neuroscience Company to Turbocharge Therapeutics Pipeline Beyond Non-Hallucinogenic Analogs of First-Gen Psychedelics to Advance Psychoplastogens in Novel Chemical Space BOSTON, Feb. 14, 2023 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions…

Source